Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$7.23
+4.2%
$6.60
$4.34
$12.38
$348.86M0.46164,658 shs212,921 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$2.00
-0.5%
$2.30
$0.98
$3.44
$81.05M0.2626,759 shs53,850 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.94
+8.4%
$1.29
$0.69
$3.94
$354.78M0.826.06 million shs9.26 million shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$7.96
+7.6%
$5.56
$2.76
$8.47
$354.78M0.457,653 shs47,564 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
+1.46%+4.68%+8.44%+41.63%-12.92%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-1.95%-1.95%-12.99%+19.32%+7.49%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-2.98%+10.49%+50.42%+145.21%-2.72%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
+4.28%+8.04%+41.97%+92.84%+57.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.1335 of 5 stars
3.60.00.00.02.73.30.0
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.269 of 5 stars
3.43.00.03.93.31.70.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
0.6545 of 5 stars
1.33.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00204.29% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00260.82% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.000.45% Upside

Current Analyst Ratings Breakdown

Latest BYSI, AURA, NBTX, and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M46.08N/AN/A($0.37) per share-5.41
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M1.16$0.03 per share74.50($1.97) per share-0.98
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$11.61M-32.89N/AN/A($1.51) per share-5.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/13/2025 (Estimated)
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/A8/14/2025 (Estimated)
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.49N/AN/AN/A-35.84%-0.91%-28.84%N/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)

Latest BYSI, AURA, NBTX, and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
8/13/2025Q2 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.04N/A-$0.04N/AN/A
8/5/2025Q2 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.49
2.49
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04

Institutional Ownership

CompanyInstitutional Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%

Insider Ownership

CompanyInsider Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
6.30%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.70%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.10 millionNot Optionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.32 million28.50 millionOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.94 million46.29 millionNot Optionable

Recent News About These Companies

Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)
Nanobiotix price target lowered to $8 from $12 at Guggenheim
Nanobiotix (NBTX) Gets a Hold from UBS
Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$7.23 +0.29 (+4.18%)
Closing price 04:00 PM Eastern
Extended Trading
$7.21 -0.02 (-0.28%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$2.00 -0.01 (-0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 +0.00 (+0.25%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.94 +0.15 (+8.38%)
Closing price 04:00 PM Eastern
Extended Trading
$1.94 0.00 (0.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$7.96 +0.56 (+7.62%)
Closing price 03:58 PM Eastern
Extended Trading
$7.98 +0.02 (+0.20%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.